Pectolinarigenin |
Catalog No.GN10183
One-Click Copy Product Info
|
Pectolinarigenin, as a flavonoids compound, which can be isolated from the aerial parts of C.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 520-12-7
Sample solution is provided at 25 µL, 10mM.
Pectolinarigenin, as a flavonoids compound, which can be isolated from the aerial parts of C. chanroenicum has been displayed biologic activities such as anti-inflammation and anti-allergy[1]. It also repressed cancer growth in vitro, including lung cancer, breast cancer and colorectal adenocarcinoma[2].
In vitro, pectolinarigenin inhibited significantly the growth of the SK-HEP-1 liver cancer cells and exhibited an IC50 of 10 µM, while against normal cells the cytotoxic effects were much less pronounced[3]. In vitro experiment it demenstrated that Pectolinarigenin at 10 µM obviously inhibited ROS accumulation after 24 h-treatment in HepG2 cells and also increased protein expression of NQO-1 and AKR1B10[4]. In vitro, 30 µM pectolinarigenin treatment suppressed melanin biosynthesis without cytotoxicity in melan-a cells[5]. Pectolinarigenin also reduced the lipid contents in vitro[6]. Treatment with 40 µM pectolinarigenin in A375 cells and in B16 cells increased >6-fold and 10-fold apoptotic rate compared with the respective untreated control groups[7].
In vivo, 10 mg/kg pectolinarigenin in mice could activate the Nrf2/ARE pathway and induced antioxidant enzymes as the same manner as the results from HepG2 cells[4]. In vivo efficacy test it shown that mice were administrated pectolinarigenin (20 mg/kg/2 days and 50 mg/kg/2 days) intraperitoneally blocked STAT3 activation and disturbed tumor growth and metastasis with superior pharmacodynamic properties[8]. In vivo test it exhibited that mice were administrated with 25 mg/kg/d orally for 7 days or 14 days effectively ameliorated kidney injury and tubulointerstitial fibrosis after unilateral ureteral obstruction (UUO) surgery[9].
References:
[1] H. Lim, et al. Anti-inflammatory activity of pectolinarigenin and pectolinarin isolated from Cirsium chanroenicum Biol. Pharm. Bull., 31 (2008), pp. 2063-2067.
[2] M. Bonesi, et al. In vitro biological evaluation of novel 7-O dialkylaminoalkyl cytotoxic pectolinarigenin derivatives against a panel of human cancer cell lines Bioorg. Med. Chem. Lett., 18 (2008), pp. 5431-5434.
[3] Liu S, et al. Pectolinarigenin flavonoid exhibits selective anti-proliferative activity in cisplatin-resistant hepatocellular carcinoma, autophagy activation, inhibiting cell migration and invasion, G2/M phase cell cycle arrest and targeting ERK1/2 MAP kinases. J BUON. 2020 Jan-Feb;25(1):415-420.
[4] Shiraiwa M, et al. Pectolinarigenin Induces Antioxidant Enzymes through Nrf2/ARE Pathway in HepG2 Cells. Antioxidants (Basel). 2022 Mar 30;11(4):675.
[5] Lee S, et al. Pectolinarigenin, an aglycone of pectolinarin, has more potent inhibitory activities on melanogenesis than pectolinarin. Biochem Biophys Res Commun. 2017;493:765-772.
[6] Zhang Y, Wan C, Song Z, Meng W, Wang S, Lan Z. Pectolinarigenin reduces the expression of sterol regulatory element-binding proteins and cellular lipid levels. Biosci Biotechnol Biochem. 2022 Aug 24;86(9):1220-1230.
[7] Deng Y, et al. Pectolinarigenin inhibits cell viability, migration and invasion and induces apoptosis via a ROS-mitochondrial apoptotic pathway in melanoma cells. Oncol Lett. 2020 Oct;20(4):116.
[8] Zhang T, et al. Pectolinarigenin acts as a potential anti-osteosarcoma agent via mediating SHP-1/JAK2/STAT3 signaling. Biomed Pharmacother. 2022 Sep;153:113323.
[9] Li Y, et al. Natural flavonoid pectolinarigenin alleviated kidney fibrosis via inhibiting the activation of TGFβ/SMAD3 and JAK2/STAT3 signaling. Int Immunopharmacol. 2021 Feb;91:107279.
| Cell experiment [1]: | |
|
Cell lines |
Osteosarcoma cells |
|
Preparation Method |
Osteosarcoma cells were seeded into 6-well plates and treated with or without 10 µM pectolinarigenin for a week. Colonies were then fixed and stained with 0.1 % crystal violet. Images were taken by an invert microscope. Colony numbers were counted manually. |
|
Reaction Conditions |
10 µM; for a week |
|
Applications |
Pectolinarigenin treatment resulted in a marked decrease in tumor cells colony numbers. Additionly, pectolinarigenin also had the pro-apoptotic propensity. |
| Animal experiment [2]: | |
|
Animal models |
male C57BL/6J mice (8-10 weeks old; 20-25 g) |
|
Preparation Method |
Forty mice were randomly assigned to five groups: Control (n = 8), HN (n = 8), Allopurinol (n = 8), PEC (Pectolinarigenin) 25 mg/kg (n = 8), PEC 50 mg/kg (n = 8). The HN model was established by feeding mice with a mixture of adenine (0.16 g/kg) and potassium oxonate (2.4 g/kg) every other day for 4 weeks, as previously described (Ren et al., 2021). Allopurinol (10 mg/kg) and PEC (25 and 50 mg/kg) were orally given daily during the experiment along with HN establishment (for 4 weeks). |
|
Dosage form |
25 and 50 mg/kg; p.o. |
|
Applications |
After allopurinol and PEC treatment, the serum levels of UA (uric acid), urea nitrogen, and creatinine were significantly decreased, and PEC at a dose of 25 mg/kg seems more superior in reducing above indexes than PEC with a higher dose (50 mg/kg). |
|
References: [1] Zhang T, et al. Pectolinarigenin acts as a potential anti-osteosarcoma agent via mediating SHP-1/JAK2/STAT3 signaling. Biomed Pharmacother. 2022 Sep;153:113323. | |
| Cas No. | 520-12-7 | SDF | |
| Chemical Name | 5,7-dihydroxy-6-methoxy-2-(4-methoxyphenyl)chromen-4-one | ||
| Canonical SMILES | COC1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O)OC)O | ||
| Formula | C17H14O6 | M.Wt | 314.29 |
| Solubility | ≥ 31.4mg/mL in DMSO | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1818 mL | 15.9089 mL | 31.8177 mL |
| 5 mM | 636.4 μL | 3.1818 mL | 6.3635 mL |
| 10 mM | 318.2 μL | 1.5909 mL | 3.1818 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)